Last reviewed · How we verify
Anti-CD20 antibodies — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-CD20 antibodies (Anti-CD20 antibodies) — Hansa Biopharma AB.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-CD20 antibodies TARGET | Anti-CD20 antibodies | Hansa Biopharma AB | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-CD20 antibodies CI watch — RSS
- Anti-CD20 antibodies CI watch — Atom
- Anti-CD20 antibodies CI watch — JSON
- Anti-CD20 antibodies alone — RSS
Cite this brief
Drug Landscape (2026). Anti-CD20 antibodies — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd20-antibodies. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab